WSJ:Training Ground for Startups in Anti-Aging Plays Long Game”

Longevity Fund founder Laura Deming is a believer that the accelerator model can be applied to moonshot biotech concepts such as staving off aging.


San Francisco Business Times: “23 Year Old Biotech Wunderkind, ANti-Aging startups find champion, funding”

Laura Deming's Age1 accelerator, backed by Marc Andreessen and Felicis Ventures, wants to create an ecosystem of entrepreneurs and mentors focused on aging-related diseases.


Techcrunch: “One of the youngest fund managers in the U.S. just launched her own accelerator, too”

The Longevity Fund has established a new accelerator program — one with backing from famed investor Marc Andreessen, the early-stage venture firm Felicis Ventures and other, unnamed investors.